Oncology
Daraxonrasib Challenges Second-Line Pancreatic Cancer Care
Median overall survival was reported at 13.2 months with daraxonrasib versus 6.6 months with chemotherapy in KRAS-mutant metastatic pancreatic cancer, but comparative uncertainty limits practice implications.
Rayan Salih · August 25, 2026 · 7 min